{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:30:37Z","timestamp":1785364237415,"version":"3.55.0"},"reference-count":21,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: Patients with moderate-to-severe psoriasis who experience inadequate response or loss of efficacy to multiple biologic agents (\u201cmulti-failure patients\u201d) represent a particularly challenging subgroup in clinical practice. Evidence regarding the efficacy of bimekizumab in this setting is still limited. This multicentre, real-life study aimed to evaluate the effectiveness, safety, and treatment persistence of bimekizumab in patients with moderate-to-severe psoriasis who had failed at least two previous biologic therapies. Methods: This multicentre, retrospective, real-life study across Italian referral centers retrospectively collected clinical data from 33 adult patients with plaque psoriasis treated with bimekizumab across Italian referral centers. Efficacy was assessed through changes in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at weeks 4 and 16. Logistic regression was performed to identify predictors of treatment response, and Kaplan\u2013Meier analysis evaluated drug survival up to 12 months. Results: The mean baseline PASI was 14.5 \u00b1 7.1, decreasing to 1.5 \u00b1 4.0 at week 16 (p &lt; 0.001). PASI90 and PASI100 responses were achieved by 57.6% and 42.4% of patients at this timepoint, respectively, while mean DLQI improved by 84.2%. In this small cohort, no significant differences in efficacy were observed according to the number or class of prior biologic failures. Genital psoriasis was associated with a lower likelihood of achieving PASI100. Adverse events were generally mild to moderate in severity and manageable in routine clinical practice. No discontinuations occurred due to lack of efficacy; all withdrawals were related to mild adverse events or personal reasons. Twelve-month drug survival reached 85.4% (95% CI 63.8\u2013100). Conclusions: Bimekizumab demonstrated rapid, marked, and sustained clinical improvements with a favorable safety profile in multi-failure psoriasis patients. These findings support its role as an effective and well-tolerated therapeutic option for individuals with highly refractory disease in real-life practice.<\/jats:p>","DOI":"10.3390\/jpm16010027","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:53:50Z","timestamp":1767610430000},"page":"27","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Bimekizumab in Multi-Failure Psoriatic Patients: A Retrospective, Real-World Multicenter Study"],"prefix":"10.3390","volume":"16","author":[{"given":"Francesca","family":"Satolli","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rech","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Psoriasis Outpatient Service, APSS (Azienda Provinciale per i Servizi Sanitari), 38122 Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5342-8147","authenticated-orcid":false,"given":"Silvia","family":"Gerosa","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bigi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Surgical, Medical, Dental & Morphological Sciences with Interest Transplant, Oncological & Regenerative Medicine, University of Modena and Reggio Emilia, 41121 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Conti","sequence":"additional","affiliation":[{"name":"Dermatologic Unit, Department of Surgery, Infermi Hospital of Rimini, auSL Romagna, 47923 Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Lernia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Surgical, Medical, Dental & Morphological Sciences with Interest Transplant, Oncological & Regenerative Medicine, University of Modena and Reggio Emilia, 41121 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita","family":"Longo","sequence":"additional","affiliation":[{"name":"Dermatology Unit and Regional Skin Bank, 47521 Cesena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5773-4362","authenticated-orcid":false,"given":"Michela","family":"Tabanelli","sequence":"additional","affiliation":[{"name":"Dermatologic Unit, Department of Surgery, Santa Maria Delle Croci Hospital of Ravenna, AUSL Romagna, 48121 Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6162-2004","authenticated-orcid":false,"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.36849\/JDD.6040","article-title":"An Overview of Biologics for Psoriasis","volume":"20","author":"Dave","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kamata, M., and Tada, Y. (2020). Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051690"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","article-title":"New Frontiers in Personalized Medicine in Psoriasis","volume":"22","author":"Camela","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s13555-023-00907-1","article-title":"Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective","volume":"13","author":"Spencer","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/09546634.2018.1427206","article-title":"Secukinumab in Multi-Failure Psoriatic Patients: The Last Hope?","volume":"29","author":"Magnano","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Orsini, D., Graceffa, D., Burlando, M., Campanati, A., Campione, E., Guarneri, C., Narcisi, A., Pella, P., Romita, P., and Travaglini, M. (2025). Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients\u2014IL PSO (Italian Landscape Psoriasis). J. Clin. Med., 14.","DOI":"10.3390\/jcm14041087"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3249041420","article-title":"The Successful Treatment with Ixekizumab in A Multi-Failure Psoriasis Patient","volume":"24","author":"Azevedo","year":"2018","journal-title":"Dermatol. Online J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s40265-021-01612-z","article-title":"Bimekizumab for the Treatment of Psoriasis","volume":"81","author":"Freitas","year":"2021","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Megna, M., Cecere, D., D\u2019Agostino, M., Tommasino, N., Lauletta, G., Esposito, V., Bianco, M., and Potestio, L. (2025). Efficacy and Tolerability of Bimekizumab within Patients with Moderate-To-Severe Plaque Psoriasis: Learnings from Real World Evidence. Expert Opin. Drug Saf., 1\u201312.","DOI":"10.1080\/14740338.2025.2553058"},{"key":"ref_10","first-page":"E107","article-title":"Real-World Experience Versus Clinical Trials: Pros and Cons in Psoriasis Therapy Evaluation","volume":"61","author":"Cinelli","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_11","first-page":"351","article-title":"Multi-Failure Psoriasis Patients: Characterization of the Patients and Response to Biological Therapy in A Multicenter Italian Cohort","volume":"63","author":"Viola","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Narcisi, A., Ibba, L., Balato, A., Bianchi, L., Brianti, P., Buononato, D., Burlando, M., Caldarola, G., and Campanati, A. (2023). Effectiveness and Safety of Bimekizumab for the Treatment of Plaque Psoriasis: A Real-Life Multicenter Study\u2014IL PSO (Italian Landscape Psoriasis). Front. Med., 10.","DOI":"10.3389\/fmed.2023.1243843"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.5826\/dpc.1502a4976","article-title":"Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy","volume":"15","author":"Dattola","year":"2025","journal-title":"Dermatol. Pr. Concept."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2393376","DOI":"10.1080\/09546634.2024.2393376","article-title":"Efficacy and Safety of Bimekizumab in Elderly Patients: Real-World Multicenter Retrospective Study\u2014IL PSO (Italian Landscape Psoriasis)","volume":"35","author":"Orsini","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/ced\/llae147","article-title":"Efficacy and Safety of Bimekizumab in Real-World Psoriasis Management: Data from Patients Who are Biologic-Naive vs. Biologic-Experienced","volume":"49","author":"Megna","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2432932","DOI":"10.1080\/09546634.2024.2432932","article-title":"Bimekizumab for the Treatment of Moderate to Severe Psoriasis: A Real-World Experience over 52 Weeks from Two Italian Dermatology Clinics","volume":"36","author":"Mortato","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00403-024-03594-w","article-title":"Long-Term Efficacy and Safety of Bimekizumab in Real-World Setting: A 52-Week Prospective Study","volume":"317","author":"Potestio","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/ced\/llae400","article-title":"The Risk of Candidiasis during Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicentre Real-World Experience\u2014IL PSO (Italian Landscape Psoriasis)","volume":"50","author":"Megna","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2024052","DOI":"10.5826\/dpc.1402a52","article-title":"Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience\u2014IL PSO (Italian Landscape Psoriasis)","volume":"14","author":"Orsini","year":"2024","journal-title":"Dermatol. Pr. Concept."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40261-025-01440-z","article-title":"Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation\u2014IL PSO (Italian Landscape Psoriasis)","volume":"45","author":"Esposito","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110328","DOI":"10.1016\/j.clim.2024.110328","article-title":"IL-17A\/F Double Producing T Cells, Unstable Tregs and Quiescent Trms in Clinically Healed Lesions are Potential Cellular Candidates for Recurrence of Psoriasis","volume":"266","author":"Peng","year":"2024","journal-title":"Clin. Immunol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/1\/27\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:06:27Z","timestamp":1767611187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/1\/27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jpm16010027"],"URL":"https:\/\/doi.org\/10.3390\/jpm16010027","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}